

PATENT
USSN 08/441,355
Docket No. 223002006313
Client Reference PP00063.021

CLAIMS AFTER AMENDMENT

In the Claims:

1-117. (Canceled)

118. (Previously presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that comprise antibodies that form an antigen-antibody complex with an amino acid sequence of at least 10 contiguous amino acids encoded by a hepatitis C virus genome.

119. (Previously presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that comprise antibodies that form an antigen-antibody complex with an HCV polypeptide sequence of at least 10 contiguous amino acid encoded by an HCV cDNA insert in the lambda gt-11 library deposited as ATCC deposit No. 40394.

120-122. (Canceled)

123. (Previously presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that comprise antibodies that form an antigen-antibody complex with an amino acid sequence of at least 10 contiguous amino acids found in Figure 90.

124. (Previously presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that comprise antibodies that form an antigen-antibody complex with an amino acid sequence of at least 10 contiguous amino acids found in Figure 14.

125. (Currently amended) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that comprise antibodies that form an antigen-antibody complex with a hepatitis C virus (HCV) polypeptide sequence of at least 10 contiguous amino acid found in Figure 62.

PATENT
USSN 08/441,355
Docket No. 223002006313
Client Reference PP00063.021

126-128. (Canceled)

129. (Previously presented) A method according to any of claims 118, 119, and 123-125 wherein said antibodies are detectable in an ELISA or radioimmunoassay.

130. (Previously presented) A method according to claim 129 wherein said ELISA or radioimmunoassay employs an antigen comprising said amino acid sequence made by recombinant expression.

131. (Previously presented) A method according to claim 130 wherein said antigen is a fusion protein.

132. (Previously presented) A method according to any of claims 118-119, and 123-125, wherein said biological samples are blood.

133-135. (Canceled)

136. (Previously presented) A method according to claim 129 wherein said biological samples are blood.

137. (Previously presented) A method according to claim 130 wherein said biological samples are blood.

138. (Previously presented) A method according to any of claims 118-119, and 123-125, wherein said biological samples are plasma.

139-141. (Canceled)

142. (Previously presented) A method according to claim 129 wherein said biological samples are plasma.

143. (Previously presented) A method according to claim 130 wherein said biological samples are plasma.

PATENT
USSN 08/441,355
Docket No. 223002006313
Client Reference PP00063.021

144. (Previously presented) A method according to any of claims 118-119, or 123-125, wherein said biological samples are sera.

145-147. (Canceled)

148. (Previously presented) A method according to claim 129 wherein said biological samples are sera.

149. (Previously presented) A method according to claim 130 wherein said biological samples are sera.

150. (Previously presented) A method according to claim 132 further comprising employing biological samples that are not selected for a preparation of blood-related products.

151. (Canceled)

152. (Previously presented) A method according to claim 138 further comprising employing biological samples that are not selected for a preparation of blood-related products.

153-157. (Canceled)

158. (Previously presented) A method according to claim 132 further comprising preparing polyclonal antibodies with the selected biological samples.

159. (Canceled)

160. (Previously presented) A method according to claim 138 further comprising preparing polyclonal antibodies with the selected biological samples.

161. (Currently amended) A method according to claim 144 further comprising preparing polyclonal antibodies with the selected biological samples.

162-163. (Canceled)

PATENT
USSN 08/441,355
Docket No. 223002006313
Client Reference PP00063.021

164. (Previously presented) A method according to claim 132 wherein the selecting is to identify an HCV positive sample for removal from the supply.

165-168. (Canceled)

169. (Previously presented) A method according to claim 136 wherein the selecting is to identify an HCV positive sample for removal from the supply.

170. (Previously presented) A method according to claim 137 wherein the selecting is to identify an HCV positive sample for removal from the supply.

171. (Previously presented) A method according to claim 138 wherein the selecting is to identify an HCV positive sample for removal from the supply.

172-174. (Cancelled)

175. (Previously presented) A method according to claim 142 wherein the selecting is to identify an HCV positive sample for removal from the supply.

176. (Previously presented) A method according to claim 143 wherein the selecting is to identify an HCV positive sample for removal from the supply.

177. (Previously presented) A method according to claim 144 wherein the selecting is to identify an HCV positive sample for removal from the supply.

178-180. (Cancelled)

181. (Previously presented) A method according to claim 148 wherein the selecting is to identify an HCV positive sample for removal from the supply.

182. (Previously presented) A method according to claim 149 wherein the selecting is to identify an HCV positive sample for removal from the supply.

PATENT
USSN 08/441,355
Docket No. 223002006313
Client Reference PP00063.021

183. (Currently amended) A method according to any one of claims 118, 119, 123, 124 or 125, wherein the selected samples comprise antibodies that form an antigen-antibody complex with an amino acid sequence of at least 15 contiguous amino acids.

184. (Previously presented) The method according to claim 118 wherein the selected samples comprise antibodies that form an antigen-antibody complex with an amino acid sequence of less than about 100 contiguous amino acids encoded by a hepatitis C virus genome.

185. (Previously presented) The method according to claim 119 wherein the selected samples comprise antibodies that form an antigen-antibody complex with an amino acid sequence of less than about 100 contiguous amino acids encoded by an HCV cDNA insert in the lambda gt-11 library deposited as ATCC deposit No. 40394.

186. (Previously presented) The method according to claim 123 wherein the selected samples comprise antibodies that form an antigen-antibody complex with an amino acid sequence of less than about 100 contiguous amino acids found in Figure 90.

187. (Previously presented) The method according to claim 124 wherein the selected samples comprise antibodies that form an antigen-antibody complex with an amino acid sequence of less than about 100 contiguous amino acids found in Figure 14.

188. (Currently amended) The method according to claim 125 wherein the selected samples comprise antibodies that form an antigen-antibody complex with an amino acid sequence of less than about 100 contiguous amino acids found in Figure 62.

189. (Previously presented) A method according to any one of claim 118, 119, 123-125, wherein the selected samples comprise one or more contiguous amino acid sequences selected from the following group:

AA1-AA50; AA1-AA84; AA9-AA177; AA1-AA120; AA35-AA45; AA50-AA100;
AA40-AA90; AA65-AA75; AA80-AA90; AA99-AA120; AA95-AA110; AA100-AA150;

PATENT
 USSN 08/441,355
 Docket No. 223002006313
 Client Reference PP00063.021

AA150-AA200; AA200-AA250; AA220-AA240; AA245-AA265; AA250-AA300; AA290-AA330; AA290-AA305; AA300-AA-350; AA310-AA330; AA350-AA400; AA405-AA495; AA400-AA450; AA437-AA582; AA450-AA500; AA475-AA495; AA500-AA550; AA511-AA690; AA515-AA550; AA550-AA600; AA550-AA625; AA575-AA605; AA600-AA650; AA600-AA625; AA635-AA665; AA650-AA700; AA645-AA680; AA700-AA750; AA700-AA725; AA725-AA775; AA770-AA790; AA750-AA800; AA800-AA815; AA850-AA875; AA800-AA850; AA920-AA990; AA850-AA900; AA920-AA945; AA940-AA965; AA950-AA1000; AA1000-AA1060; AA1000-AA1050; AA1025-AA1040; AA1075-AA1175-AA1000; AA1000-AA1060; AA1000-AA1050; AA1025-AA1040; AA1075-AA1175; AA1050-AA1200; AA1070-AA1100; AA1100-AA1140; AA1192-AA1457; AA1195-AA1250; AA1200-AA1225; AA1225-AA1250; AA1250-AA1300; AA1260-AA1310; AA1260-AA1280; AA1266-AA1428; AA1300-AA1350; AA1310-AA1340; AA1345-AA1405; AA1350-AA1400; AA1365-AA1380; AA1380-AA1405; AA1400-AA1450; AA1450-AA1500; AA1475-AA1515; AA1475-AA1500; AA1500-AA1550; AA1515-AA1550; AA1550-AA1600; AA1569-AA1931; AA1570-AA1590; AA1595-AA1610; AA1590-AA1650; AA1610-AA1645; AA1650-AA1690; AA1685-AA1770; AA1689-AA1805; AA1690-AA1720; AA1694-AA1735; AA1720-AA1745; AA1745-AA1770; AA1750-AA1800; AA1775-AA1810; AA1795-AA1850; AA1850-AA1900; AA1900-AA1950; AA1900-AA1920; AA1916-AA2021; AA1920-AA1940; AA1949-AA2124; AA1950-AA2000; AA1950-AA1985; AA2000-AA2050; AA2020-AA2045; AA2045-AA2100; AA2045-AA2070; AA2054-AA2223; AA2070-AA2100; AA2100-AA2150; AA2150-AA2220; AA2200-AA2345; AA2250-AA2330; AA2265-AA2280; AA2280-AA2290; AA2287-AA2385; AA2300-AA2350; AA2350-AA2400; AA2345-AA2415; AA2345-AA2375; AA2348-AA2464; AA2370-AA2410; AA2400-AA2450; AA2400-AA2425; AA2415-AA2450; AA2445-AA2500; AA2371-AA2502; AA2500-AA2550; AA2505-AA2540; AA2550-AA2600; AA2560-AA2580; AA2600-AA2650; AA2620-AA2650; AA2650-AA2700; AA2655-AA2670; AA2670-AA2700; AA2700-AA2750; AA2750-AA2800; AA2755-AA2780; AA2780-AA2830; AA2785-AA2810; AA2796-AA2886; AA2810-AA2825; AA2800-AA2850; AA2850-AA2900; AA2900-AA2950; AA2910-AA2930; and AA2925-AA2950;

PATENT
USSN 08/441,355
Docket No. 223002006313
Client Reference PP00063.021

wherein the contiguous amino acid sequence is depicted according to the formula AA_x-AA_y , x and y denoting amino acid numbers HCV-1 polyprotein or corresponding regions of other HCV isolates.

190. (Previously presented) The method according to claim 189 wherein said antibodies are detectable in an ELISA or radioimmunoassay.

191. (Previously presented) The method according to claim 190 wherein said ELISA or radioimmunoassay employs an antigen comprising said amino acid sequence made by recombinant expression.

192. (Previously presented) The method according to claim 190 wherein said biological samples are blood.

193. (Previously presented) The method according to claim 191 wherein said biological samples are blood.

194. (Previously presented) The method according to claim 190 wherein said biological samples are plasma.

195. (Previously presented) The method according to claim 191 wherein said biological samples are plasma.

196. (Previously presented) The method according to claim 190 wherein said biological samples are sera.

197. (Previously presented) The method according to claim 191 wherein said biological samples are sera.

198. (Previously presented) The method according to claim 192 wherein the selecting is to identify an HCV positive sample for removal from the supply.

199. (Previously presented) The method according to claim 193 wherein the selecting is to identify an HCV positive sample for removal from the supply.

PATENT
USSN 08/441,355
Docket No. 223002006313
Client Reference PP00063.021

200. (Previously presented) The method according to claim 194 wherein the selecting is to identify an HCV positive sample for removal from the supply.

201. (Previously presented) The method according to claim 195 wherein the selecting is to identify an HCV positive sample for removal from the supply.

202. (Previously presented) The method according to claim 196 wherein the selecting is to identify an HCV positive sample for removal from the supply.

203. (Previously presented) The method according to claim 197 wherein the selecting is to identify an HCV positive sample for removal from the supply.

204. (Previously presented) A method according to any one of claims 118, 119, 123-125, wherein the selected samples comprise one or more contiguous amino acid sequences selected from the following group:

AA1-AA84; AA437-AA582; AA511-AA690; AA9-AA177; AA1192-AA1457;
AA1266-AA1428; AA1694-AA1735; AA1689-AA1805; AA1916-AA2021; AA1949-AA2124;
AA2054-AA2223; AA2200-AA3325; AA2287-AA2385; AA2348-AA2464; AA2371-AA2502;
AA2796-AA2886; AA1569-AA1931,

wherein the contiguous amino acid sequence is depicted according to the formula AA_x-AA_y , x and y denoting amino acid numbers HCV-1 polyprotein or corresponding regions of other HCV isolates.

205. (Previously presented) The method according to claim 204 wherein said antibodies are detectable in an ELISA or radioimmunoassay.

206. (Previously presented) The method according to claim 205 wherein said ELISA or radioimmunoassay employs an antigen comprising said amino acid sequence made by recombinant expression.

PATENT
USSN 08/441,355
Docket No. 223002006313
Client Reference PP00063.021

207. (Previously presented) The method according to claim 205 wherein said biological samples are blood.

208. (Previously presented) The method according to claim 206 wherein said biological samples are blood.

209. (Previously presented) The method according to claim 205 wherein said biological samples are plasma.

210. (Previously presented) The method according to claim 206 wherein said biological samples are plasma.

211. (Previously presented) The method according to claim 205 wherein said biological samples are sera.

212. (Previously presented) The method according to claim 206 wherein said biological samples are sera.

213. (Previously presented) The method according to claim 207 wherein the selecting is to identify an HCV positive sample for removal from the supply.

214. (Previously presented) The method according to claim 208 wherein the selecting is to identify an HCV positive sample for removal from the supply.

215. (Previously presented) The method according to claim 209 wherein the selecting is to identify an HCV positive sample for removal from the supply.

216. (Previously presented) The method according to claim 210 wherein the selecting is to identify an HCV positive sample for removal from the supply.

PATENT
USSN 08/441,355
Docket No. 223002006313
Client Reference PP00063.021

217. (Previously presented) The method according to claim 211 wherein the selecting is to identify an HCV positive sample for removal from the supply.

218. (Previously presented) The method according to claim 212 wherein the selecting is to identify an HCV positive sample for removal from the supply.

219. (Previously presented) A method according to any one of claim 118, 119, 123-125, wherein the selected samples comprise one or more contiguous amino acid sequences selected from the following group:

AA1694-AA1735; AA1569-AA1931; AA1192-AA1457; AA1-AA84; and AA9-AA177, wherein the contiguous amino acid sequence is depicted according to the formula AA_x-AA_y , x and y denoting amino acid numbers of HCV-1 polypeptide or corresponding regions of other HCV isolates.

220-283. (Canceled)

284. (Previously presented) A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which do not comprise antibodies that form an antigen-antibody complex with an amino acid sequence of at least 10 contiguous amino acids encoded by a hepatitis C virus genome.

285. (Canceled)

286. (Previously presented) A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which do not comprise antibodies that form an antigen-antibody complex with an amino acid sequence of at least 10 contiguous amino acids encoded by at least one of the HCV cDNA inserts in a lambda gt-11 library deposited as ATCC Deposit No. 40394.

287. (Canceled)

288. (Previously presented) A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which do not comprise antibodies that form an antigen-antibody complex with an amino acid sequence of at least 10 contiguous amino acids found in Figure 90.

289. (Currently amended) A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which do not comprise antibodies that form an antigen-antibody complex with an amino acid sequence of at least 10 contiguous amino acids found in Figure 14.

290. (Previously presented) A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which do not comprise antibodies that form an antigen-antibody complex with an amino acid sequence of at least 10 contiguous amino acids found in Figure 62.

291-296. (Canceled)

297. (Currently amended) A method according to any of claims 284, 286 or 288-290 wherein said biological samples are blood.

298-301 (Canceled)

302. (Currently amended) A method according to any of claims 284, 286 or 288-290 wherein said biological samples are plasma.

303-306. (Canceled)

307. (Currently amended) A method according to any of claims 284, 286, or 288-290 wherein said biological samples are sera.

308-311. (Cancelled)

PATENT
 USSN 08/441,355
 Docket No. 223002006313
 Client Reference PP00063.021

312. (Currently amended) A method according to any of claims 118 119, or 123-125 further comprising employing biological samples that are not selected for a preparation of blood-related products.

313. (Currently amended) A method according to claim 144 further comprising employing biological samples that are not selected for a preparation of blood-related products.

314. (Currently amended) A method according to claim 130 further comprising employing biological samples that are not selected for a preparation of blood-related products.

315. (Currently amended) A method according to any of claims 284, 286, 288, 289 or 290 further comprising employing biological samples that are selected for a preparation of blood-related products.

316-320. (Canceled)

321. (Currently amended) A method according to any of claim 284, 286, 288, 289 or 290 wherein said selected samples are supply samples for preparation of blood products.

322-323. (Canceled)

324. (Currently amended) The method according to claim 284 wherein the selected samples comprise antibodies that form an antigen-antibody complex with an amino acid sequence of less than about 100 contiguous amino acids encoded by a hepatitis C virus genome.

325. (Currently amended) The method according to claim 286 wherein the selected samples comprise antibodies that form an antigen-antibody complex with an amino acid sequence of less than about 100 contiguous amino acids encoded by an HCV cDNA insert in the lambda gt-11 library deposited as ATCC deposit No. 40394.

326. (Currently amended) The method according to claim 288 wherein the selected samples comprise antibodies that form an antigen-antibody complex with an amino acid sequence of less than about 100 contiguous amino acids found in Figure 90.

PATENT
USSN 08/441,355
Docket No. 223002006313
Client Reference PP00063.021

327. (Currently amended) A method according to any of claims 284, 286, 288-290 wherein the contiguous sequence is found within the sequence selected from the group consisting of:

AA1-AA50; AA1-AA84; AA9-AA177; AA1-AA120; AA35-AA45; AA50-AA100; AA40-AA90; AA65-AA75; AA80-AA90; AA99-AA120; AA95-AA110; AA100-AA150; AA150-AA200; AA200-AA250; AA220-AA240; AA245-AA265; AA250-AA300; AA290-AA330; AA290-AA305; AA300-AA350; AA310-AA330; AA350-AA400; AA405-AA495; AA400-AA450; AA437-AA582; AA450-AA500; AA475-AA495; AA500-AA550; AA511-AA690; AA515-AA550; AA550-AA600; AA550-AA625; AA575-AA605; AA600-AA650; AA600-AA625; AA635-AA665; AA650-AA700; AA645-AA680; AA700-AA750; AA700-AA725; AA725-AA775; AA770-AA790; AA750-AA800; AA800-AA815; AA850-AA875; AA800-AA850; AA920-AA990; AA850-AA900; AA920-AA945; AA940-AA965; AA950-AA1000; AA1000-AA1060; AA1000-AA1050; AA1025-AA1040; AA1075-AA1175; AA1000-AA1060; AA1000-AA1050; AA1025-AA1040; AA1075-AA1175; AA1050-AA1200; AA1070-AA1100; AA1100-AA1140; AA1192-AA1457; AA1195-AA1250; AA1200-AA1225; AA1225-AA1250; AA1250-AA1300; AA1260-AA1310; AA1260-AA1280; AA1266-AA1428; AA1300-AA1350; AA1310-AA1340; AA1345-AA1405; AA1350-AA1400; AA1365-AA1380; AA1380-AA1405; AA1400-AA1450; AA1450-AA1500; AA1475-AA1500; AA1500-AA1550; AA1515-AA1550; AA1550-AA1600; AA1569-AA1931; AA1570-AA1590; AA1595-AA1610; AA1590-AA1650; AA1610-AA1645; AA1650-AA1690; AA1685-AA1770; AA1689-AA1805; AA1690-AA1720; AA1694-AA1735; AA1720-AA1745; AA1745-AA1770; AA1750-AA1800; AA1775-AA1810; AA1795-AA1850; AA1850-AA1900; AA1900-AA1950; AA1900-AA1920; AA1916-AA2021; AA1920-AA1940; AA1949-AA2124; AA1950-AA2000; AA1950-AA1985; AA2000-AA2050; AA2020-AA2045; AA2045-AA2100; AA2045-AA2070; AA2054-AA2223; AA2070-AA2100; AA2100-AA2150; AA2150-AA2220; AA2200-AA2345; AA2250-AA2330; AA2265-AA2280; AA2280-AA2290; AA2287-AA2385; AA2300-AA2350; AA2350-AA2400; AA2345-AA2415; AA2345-AA2375; AA2348-AA2464; AA2370-AA2410; AA2400-AA2450; AA2400-AA2425; AA2415-AA2450; AA2445-AA2500; AA2371-AA2502; AA2500-AA2550; AA2505-AA2540; AA2550-AA2600; AA2560-AA2580; AA2600-AA2650; AA2620-AA2650; AA2650-AA2700;

PATENT
 USSN 08/441,355
 Docket No. 223002006313
 Client Reference PP00063.021

AA2655-AA2670; AA2670-AA2700; AA2700-AA2750; AA2750-AA2800; AA2755-AA2780;
 AA2780-AA2830; AA2785-AA2810; AA2796-AA2886; AA2810-AA2825; AA2800-AA2850;
 AA2850-AA2900; AA2900-AA2950; AA2910-AA2930; and AA2925-AA2950,
 wherein the contiguous amino acid sequence is depicted according to the formula AA_x-AA_y, x
 and y denoting amino acid numbers HCV-1 polyprotein or corresponding regions of other HCV
 isolates.

328-329. (Canceled)

330. (Currently amended) The method according to claim 327 wherein said biological
 samples are blood.

331. (Canceled)

332. (Currently amended) The method according to claim 327 wherein said biological
 samples are sera.

333. (Canceled)

334. (Currently amended) The method according to claim 327 wherein said biological
 samples are plasma.

335. (Canceled)

336. (Currently amended) A method according to any of claims 284, 286 or 288-290
 wherein the contiguous sequence is found within the sequence selected from the group consisting
 of:

AA1-AA84; AA37-AA582; AA511-AA690; AA9-AA177; AA1192-AA1457; AA1266-
 AA1428; AA1694-AA1735; AA1689-AA1805; AA1916-AA2021; AA1949-AA2124; AA2054-
 AA2223; AA2200-AA3325; AA2287-AA2385; AA2348-AA2464; AA2371-AA2502; AA2796-
 AA2886; AA1569-AA1931, wherein the contiguous amino acid sequence is depicted according

PATENT
USSN 08/441,355
Docket No. 223002006313
Client Reference PP00063.021

to the formula AA_x-AA_y, x and y denoting amino acid numbers HCV-1 polypeptide or corresponding regions of other HCV isolates.

337-338. (Canceled)

339. (Currently amended) The method according to claim 336 wherein said biological samples are blood.

340. (Canceled)

341. (Currently amended) The method according to claim 336 wherein said biological samples are plasma.

342. (Canceled)

343. (Currently amended) The method according to claim 336 wherein said biological samples are sera.

344. (Canceled)

345. (New) A method according to claims 284, 286, or 288-290 wherein the selected samples comprise one or more contiguous amino acid sequences selected from the following group:

AA1-AA84; AA437-AA582; AA511-AA690; AA9-AA177; AA1192-AA1457;
AA1266-AA1428; AA1694-AA1735; AA1689-AA1805; AA1916-AA2021; AA1949-AA2124;
AA2054-AA2223; AA2200-AA3325; AA2287-AA2385; AA2348-AA2464; AA2371-AA2502;
AA2796-AA2886; AA1569-AA1931,

wherein the contiguous amino acid sequence is depicted according to the formula AA_x-AA_y, x and y denoting amino acid numbers HCV-1 polypeptide or corresponding regions of other HCV isolates.

PATENT
USSN 08/441,355
Docket No. 223002006313
Client Reference PP00063.021

346. (New) A method according to claim 345 wherein said biological samples are blood.

347. (New) A method according to claim 345 wherein said biological samples are plasma.

348. (New) A method according to claim 345 wherein said biological samples are sera.

349. (New) A method according to claim 297 wherein said contiguous amino acid sequence is at least 15 amino acids.

350. (New) A method according to claim 302 wherein said contiguous amino acid sequence is at least 15 amino acids.

351. (New) A method according to claim 307 wherein said contiguous amino acid sequence is at least 15 amino acids.

352. (New) A method according to claim 315 wherein said contiguous amino acid sequence is at least 15 amino acids.

353. (New) A method according to claim 321 wherein said contiguous amino acid sequence is at least 15 amino acids.

354. (New) A method according to claim 349 wherein said contiguous amino acid sequence is less than about 100 contiguous amino acids.

355. (New) A method according to claim 350 wherein said contiguous amino acid sequence is less than about 100 contiguous amino acids.

PATENT
USSN 08/441,355
Docket No. 223002006313
Client Reference PP00063,021

356. (New) A method according to claim 351 wherein said contiguous amino acid sequence is less than about 100 contiguous amino acids.

357. (New) A method according to claim 352 wherein said contiguous amino acid sequence is less than about 100 contiguous amino acids.

358. (New) A method according to claim 353 wherein said contiguous amino acid sequence is less than about 100 contiguous amino acids.

359. (New) A method according to claim 137 wherein said contiguous amino acid sequence is at least 15 amino acids.

360. (New) A method according to claim 143 wherein said contiguous amino acid sequence is at least 15 amino acids.

361. (New) A method according to claim 149 wherein said contiguous amino acid sequence is at least 15 amino acids.

362. (New) A method according to claim 136 wherein said contiguous amino acid sequence is at least 15 amino acids

363. (New) A method according to claim 142 wherein said contiguous amino acid sequence is at least 15 amino acids.

364. (New) A method according to claim 148 wherein said contiguous amino acid sequence is at least 15 amino acids.

365. (New) A method according to claim 150 wherein said contiguous amino acid sequence is at least 15 amino acids.

PATENT
USSN 08/441,355
Docket No. 223002006313
Client Reference PP00063.021

366. (New) A method according to claim 152 wherein said contiguous amino acid sequence is at least 15 amino acids.

367. (New) A method according to claim 313 wherein said contiguous amino acid sequence is at least 15 amino acids.

368. (New) A method according to claim 132 wherein said contiguous amino acid sequence is at least 15 amino acids.

369. (New) A method according to claim 138 wherein said contiguous amino acid sequence is at least 15 amino acids.

370. (New) A method according to claim 144 wherein said contiguous amino acid sequence is at least 15 amino acids.

371. (New) A method according to claim 359 wherein said contiguous amino acid sequence is less than about 100 contiguous amino acids.

372. (New) A method according to claim 360 wherein said contiguous amino acid sequence is less than about 100 contiguous amino acids.

373. (New) A method according to claim 361 wherein said contiguous amino acid sequence is less than about 100 contiguous amino acids.

374. (New) A method according to claim 362 wherein said contiguous amino acid sequence is less than about 100 contiguous amino acids.

375. (New) A method according to claim 363 wherein said contiguous amino acid sequence is less than about 100 contiguous amino acids.

PATENT
USSN 08/441,355
Docket No. 223002006313
Client Reference PP00063.021

376. (New) A method according to claim 364 wherein said contiguous amino acid sequence is less than about 100 contiguous amino acids.

377. (New) A method according to claim 365 wherein said contiguous amino acid sequence is less than about 100 contiguous amino acids.

378. (New) A method according to claim 366 wherein said contiguous amino acid sequence is less than about 100 contiguous amino acids.

379. (New) A method according to claim 367 wherein said contiguous amino acid sequence is less than about 100 contiguous amino acids.

380. (New) A method according to claim 368 wherein said contiguous amino acid sequence is less than about 100 contiguous amino acids.

381. (New) A method according to claim 369 wherein said contiguous amino acid sequence is less than about 100 contiguous amino acids.

382. (New) A method according to claim 370 wherein said contiguous amino acid sequence is less than about 100 contiguous amino acids.

383. (New) The method according to claim 183 wherein said contiguous amino acid sequence is less than about 100 amino acids.